T1 Energy Sets Next Week for Q2 Earnings Release
T1 Energy Inc. (NYSE: TE) shares lost momentum Friday, the company having announced this morning that the Company has rescheduled its second quarter earnings release and conference call to August 20, 2025. T1’s decision to reschedule the earnings release is to accommodate the Company’s decision to delay the filing of its Quarterly Report on Form 10-Q as permitted under SEC Rules.The Company filed a Form 12b-25 notifying the U.S. Securities and Exchange Commission earlier today.The change to T1’s 10-Q filing timeline and Q2 reporting schedule relates to the presentation of non-cash amortization of certain customer contracts totaling $11.2 million in the Company’s Q1 2025 financials. The presentation has no impact on T1’s net loss, financial position, liquidity, cash flow, historical management compensation, or debt covenant compliance. The presentation is being examined to determine if it was improper. In addition, the Company is finalizing disclosure and impact on the Company from the material definitive agreements that the Company disclosed on the current report on Form 8-K on August 14, 2025.The Company expects to issue the second quarter press release at or around 6:00 am Eastern Daylight Time and the conference call is scheduled to begin at 8:00 am Eastern Daylight Time.TE shares stumbled $2.23, or 1.1%, to $204.94.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


